Abstract: Purpose: This study aimed to determine whether the 21-Gene Breast Recurrence Score® assay from primary breast tissue predicts the prognosis of patients with hormone receptor-positive and human epidermal growth factor 2-negative advanced breast cancers (ABCs) treated with fulvestrant monotherapy (Group A) and the addition of palbociclib combined with fulvestrant (Group B), which included those who had progression in Group A from the Japan Breast Cancer Research Group-M07 (FUTURE trial).
Methods: Progression-free survival (PFS) and overall survival (OS) were compared using the log-rank test and Cox regression analysis based on original recurrence score (RS) categories (Low: 0-17, Intermediate: 18-30, High: 31-100) by treatment groups (A and B) and types of ABCs (recurrence and de novo stage IV).
Results: In total, 102 patients [Low: n = 44 (43.1%), Intermediate: n = 38 (37.5%), High: n = 20 (19.6%)] in Group A, and 45 in Group B, who had progression in Group A were analyzed. The median follow-up time was 23.8 months for Group A and 8.9 months for Group B. Multivariate analysis in Group A showed that low-risk [hazard ratio (HR) 0.15, 95% confidence interval (CI) 0.04-0.53, P = 0.003] and intermediate-risk (HR 0.22, 95% CI 0.06-0.78) with de novo stage IV breast cancer were significantly associated with better prognosis compared to high-risk. However, no significant difference was observed among patients with recurrence. No prognostic significance was observed in Group B.
Conclusion: We found a distinct prognostic value of the 21-Gene Breast Recurrence Score® assay by the types of ABCs and a poor prognostic value of the high RS for patients with de novo stage IV BC treated with fulvestrant monotherapy. Further validations of these findings are required.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
References: Iwamoto T, Fukui N, Kinoshita T et al (2016) Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2006. Breast Cancer 23:62–72. https://doi.org/10.1007/s12282-015-0646-3. (PMID: 10.1007/s12282-015-0646-326464009)
Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339(14):979–984. (PMID: 10.1056/NEJM199810013391407)
Higgins MJ, Wolff AC (2008) Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park NY) 22:614–623; discussion 623, 627–629.
Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. https://doi.org/10.1038/35021093. (PMID: 10.1038/3502109310963602)
National Comprehensive Cancer Network Version 4.2023. https://www.nccn.org/Home.
Paik S, Kim C, Baehner FL et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. (PMID: 10.1056/NEJMoa04158815591335)
Sparano JA, Gray RJ, Makower DF et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005–2014. https://doi.org/10.1056/NEJMoa1510764. (PMID: 10.1056/NEJMoa151076426412349)
Sparano JA, Gray RJ, Makower DF et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379:111–121. https://doi.org/10.1056/NEJMoa1804710. (PMID: 10.1056/NEJMoa180471029860917)
Sparano JA, Gray RJ, Ravdin PM et al (2019) Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 380:2395–2405. https://doi.org/10.1056/NEJMoa1904819. (PMID: 10.1056/NEJMoa190481931157962)
Kalinsky K, Barlow WE, Gralow JR et al (2021) 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 385:2336–2347. https://doi.org/10.1056/NEJMoa2108873. (PMID: 10.1056/NEJMoa210887334914339)
King TA, Lyman JP, Gonen M et al (2016) Prognostic impact of 21-Gene Recurrence Score in patients with stage IV breast cancer: TBCRC 013. J Clin Oncol 34:2359–2365. https://doi.org/10.1200/JCO.2015.63.1960. (PMID: 10.1200/JCO.2015.63.196027001590)
Watanabe K, Niikura N, Kikawa Y et al (2023) Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial). Breast Cancer Res Treat. https://doi.org/10.1007/s10549-023-06911-5. (PMID: 10.1007/s10549-023-06911-537875670)
Cronin M, Pho M, Dutta D et al (2004) Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164:35–42. https://doi.org/10.1016/S0002-9440(10)63093-3. (PMID: 10.1016/S0002-9440(10)63093-314695316)
Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800. https://doi.org/10.1056/NEJMra0801289. (PMID: 10.1056/NEJMra080128919228622)
Bidard F-C, Jacot W, Kiavue N et al (2021) Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-negative metastatic breast cancer: the STIC CTC randomized clinical trial. JAMA Oncol 7:34–41. https://doi.org/10.1001/jamaoncol.2020.5660. (PMID: 10.1001/jamaoncol.2020.566033151266)
Iwamoto T, Lee J-S, Bianchini G et al (2011) First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Res Treat 130(1):155–164. (PMID: 10.1007/s10549-011-1706-921833625)
Niikura N, Iwamoto T, Masuda S et al (2012) Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci 103:1508–1512. https://doi.org/10.1111/j.1349-7006.2012.02319.x. (PMID: 10.1111/j.1349-7006.2012.02319.x22537114)
Iwamoto T, Kelly C, Mizoo T et al (2016) Relative prognostic and predictive value of gene signature and histologic grade in estrogen receptor-positive, HER2-negative breast cancer. Clin Breast Cancer 16:95-100.e1. https://doi.org/10.1016/j.clbc.2015.10.004. (PMID: 10.1016/j.clbc.2015.10.00426631838)
Ma CX, Reinert T, Chmielewska I, Ellis MJ (2015) Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer 15:261–275. https://doi.org/10.1038/nrc3920. (PMID: 10.1038/nrc392025907219)
Toy W, Shen Y, Won H et al (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45:1439–1445. https://doi.org/10.1038/ng.2822. (PMID: 10.1038/ng.282224185512)
Robinson DR, Wu Y-M, Vats P et al (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45:1446–1451. https://doi.org/10.1038/ng.2823. (PMID: 10.1038/ng.282324185510)
Turner NC, Swift C, Kilburn L et al (2020) ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the Phase III SoFEA and EFECT trials. Clin Cancer Res 26:5172–5177. https://doi.org/10.1158/1078-0432.CCR-20-0224. (PMID: 10.1158/1078-0432.CCR-20-022432546646)
Condorelli R, Spring L, O’Shaughnessy J et al (2018) Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol 29:640–645. https://doi.org/10.1093/annonc/mdx784. (PMID: 10.1093/annonc/mdx78429236940)
O’Leary B, Hrebien S, Morden JP et al (2018) Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun 9:896. https://doi.org/10.1038/s41467-018-03215-x. (PMID: 10.1038/s41467-018-03215-x29497091)
Tolaney SM, Toi M, Neven P et al (2022) Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant. Clin Cancer Res 28:1500–1506. https://doi.org/10.1158/1078-0432.CCR-21-3276. (PMID: 10.1158/1078-0432.CCR-21-327635121623)
Iwamoto T, Niikura N, Watanabe K et al (2023) Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-023-07144-2. (PMID: 10.1007/s10549-023-07144-237875670)
Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446–1452. https://doi.org/10.1093/jnci/djp335. (PMID: 10.1093/jnci/djp33519815849)
Iwamoto T, Niikura N, Ogiya R et al (2019) Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples. Sci Rep 9:13343. https://doi.org/10.1038/s41598-019-50099-y. (PMID: 10.1038/s41598-019-50099-y31527824)
Processing Request
No Comments.